Corporate News Blog - Titan Pharma and Opiant Pharma Collaborate to Discover a New Approach for Treatment of Opioid Use Disorder

LONDON, UK / ACCESSWIRE / October 4, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=TTNP. The Company announced on October 02, 2017, collaboration with Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) for exploring an innovative approach for the prevention of opioid relapse and overdose in individuals with opioid use disorder. Both are specialty pharmaceuticals Companies that develop therapeutics for select chronic diseases. For immediate access to our complimentary reports, including today's coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on TTNP; also brushing on OPNT. Go directly to your stock of interest and access today's free coverage at:

http://protraderdaily.com/optin/?symbol=TTNP

http://protraderdaily.com/optin/?symbol=OPNT

The companies intend to conduct a feasibility evaluation of a subcutaneous implant leveraging Titan Pharma's proprietary ProNeura™ sustained release technology for administering an opioid antagonist. They believe that a product that offers non-fluctuating, therapeutic levels of an opioid antagonist, endlessly for up to 6 months would be ideal for the prevention of opioid relapse and overdose.

Risk of Opioid Relapse and Overdose

The relapse and fatal overdose among patients suffering from opioid use disorder is much higher than that in any other form of drug addiction. In case of opioid disorder, around 91% of the patients undergoing recovery experience a relapse. And for nearly 59%, the relapse happens within the first week of sobriety itself. Approximately 80% relapse within a month after being discharged from a treatment or detox program.

Moreover, the risk of a fatal overdose is at its peak during a relapse. For a long-term opioid user, even a small dose of opioids after a period of abstinence can result in an overdose.

An Unmet Market Need

Roger Crystal, CEO and M.D. at Opiant Pharma, revealed that as of now, there is only one FDA-approved opioid antagonist for relapse prevention, which is a monthly depot injection of naltrexone.

He shared that a product with a six-month duration would enable patients to be opioid-free for a longer period. It would make the way for long-term recovery, and more importantly, relapse and overdose prevention. In case of a six-month duration treatment, patients would only need to make one good decision, i.e. to initiate therapy. This itself is critical as the longer patients receive pharmacological treatment, the less likely they are to relapse and perhaps overdose.

Collaboration to Speed up Evaluation

Sunil Bhonsle, President and CEO at Titan Pharma, announced that Titan Pharma is pleased to collaborate with Opiant Pharma on this imperative task of discovering the appropriate addition of an opioid antagonist implant to the armamentarium of products to treat opioid use disorder. He stated that Titan Pharma's knowledge from developing the FDA-approved Probuphine® (buprenorphine) implant for the maintenance treatment of opioid addiction along with the drug development expertise of both Companies would help complete the evaluation more efficiently, and hopefully with a fruitful result.

Other Feasibility Evaluations in Progress for Titan Pharma

• Titan Pharma consistently works to find more and more opportunities for increasing the use of its ProNeura long-term, continuous drug delivery platform.

• The Company initiated a Phase-1/2 clinical study of a ropinirole implant for treating Parkinson's disease.

• Besides, its implantable triiodothyronine (T3) product for the treatment of hypothyroidism is completing non-clinical development focused on formulation optimization.

• Moreover, Titan Pharma is working with the Walter Reed Army Institute of Research and the Southwest Research Institute for the early non-clinical evaluation of the implant drug delivery platform in malaria prophylaxis.

• Furthermore, the feasibility evaluations for ProNeura in the area of chronic pain treatment are currently in progress, with a superficially acting Kappa opioid receptor agonist. Evaluations are also ongoing for treatment of type-2 diabetes with currently approved peptides.

Opiant Pharma's Work in the Addiction Space

Opiant Pharma is dedicated towards innovation and product development in the addiction space. It has been developing additional therapies for opioid use disorder, such as enhancing the pre-clinical development of its heroin vaccine candidate. Walter Reed Army Institute of Research and the National Institute on Drug Abuse (NIDA) licensed this heroin vaccine candidate in October 2016. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets.

Besides, Opiant's pipeline of nasal opioid antagonists addresses alcohol abuse as well as eating disorders. The Company also continues to maintain an active presence in national organizations such as the National Institutes of Health (NIH). In fact, Dr. Crystal was recently invited to testify before the President's Commission on Combating Drug Addiction and the Opioid Crisis.

Last Close Stock Review

On Tuesday, October 03, 2017, the stock closed the trading session at $1.98, advancing 6.76% from its previous closing price of $1.85. A total volume of 279.70 thousand shares have exchanged hands, which was higher than the 3-month average volume of 117.76 thousand shares. Titan Pharma's stock price surged 23.44% in the last one month and 3.95% in the previous three months. The stock currently has a market cap of $41.87 million.

Opiant Pharma's share price finished yesterday's trading session at $31.80, declining 8.59%. A total volume of 76.21 thousand shares have exchanged hands. The Company's stock price soared 396.88% in the last three months, 310.32% in the past six months, and 281.52% in the previous twelve months. Additionally, the stock skyrocketed 466.84% since the start of the year. Shares of the Company have a PE ratio of 12.69 and currently have a market cap of $66.14 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily